U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H24N2O2.C7H6O3
Molecular Weight 462.5385
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of QUININE SALICYLATE

SMILES

C=C[C@@]1([H])CN2CC[C@@]1([H])C[C@@]2([H])[C@@]([H])(c3ccnc4ccc(cc34)OC)O.c1ccc(c(c1)C(=O)O)O

InChI

InChIKey=MAYUSTFJKJSJNC-DSXUQNDKSA-N
InChI=1S/C20H24N2O2.C7H6O3/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;8-6-4-2-1-3-5(6)7(9)10/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;1-4,8H,(H,9,10)/t13-,14-,19-,20+;/m0./s1

HIDE SMILES / InChI

Molecular Formula C7H6O3
Molecular Weight 138.121
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C20H24N2O2
Molecular Weight 324.4175
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Quinine soluble salts possess an extremely bitter taste, that may have a perplexing problem especially to children. That is why one of the most common combinations for oral administration is a slightly soluble quinine salicylate salt. It is known that now quinine is used in the absence of artemisin combination therapies (ARTs) to treat CQ resistant (CQR) P. falciparum malaria. Although the precise mechanism of the antimalarial activity of quinine is not completely understood, it can act via the inhibition on nucleic acid synthesis, on protein synthesis, and on glycolysis in Plasmodium falciparum, and also drug can affect via the binding with hemazoin in parasitized erythrocytes.

CNS Activity

Curator's Comment:: The ratio of cerebrospinal fluid to free (unbound) plasma quinine was 0.55 /- 0.33 which suggests that quinine does not freely cross the blood-brain barrier.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative

Sample Use Guides

Quinine tablets given at 10mg/kg 8 hourly for 7 days
Route of Administration: Oral
In Vitro Use Guide
Prior to treatment, the in vitro susceptibility of isolates of P. falciparum to quinine was determined using the standardized procedure recommended by WHO. The minimum inhibitory concentration (MIC) was defined as the lowest concentration that completely inhibited schizont formation. The MICs for quinine (mean, 3.02 uM) were significantly greater.
Substance Class Chemical
Created
by admin
on Sat Jun 26 08:26:21 UTC 2021
Edited
by admin
on Sat Jun 26 08:26:21 UTC 2021
Record UNII
6DY04L71DR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
QUININE SALICYLATE
WHO-DD  
Common Name English
CHININUM SALICYLICUM
HPUS  
Common Name English
CINCHONAN-9-OL, 6'-METHOXY-, (8.ALPHA.,9R)-, 2-HYDROXYBENZOATE (1:1)
Common Name English
QUININE SALICYLATE [WHO-DD]
Common Name English
QUININE, MONOSALICYLATE
Common Name English
CHININUM SALICYLICUM [HPUS]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 310.547
Created by admin on Sat Jun 26 08:26:22 UTC 2021 , Edited by admin on Sat Jun 26 08:26:22 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL170
Created by admin on Sat Jun 26 08:26:22 UTC 2021 , Edited by admin on Sat Jun 26 08:26:22 UTC 2021
PRIMARY
PUBCHEM
71794
Created by admin on Sat Jun 26 08:26:22 UTC 2021 , Edited by admin on Sat Jun 26 08:26:22 UTC 2021
PRIMARY
ECHA (EC/EINECS)
212-027-7
Created by admin on Sat Jun 26 08:26:22 UTC 2021 , Edited by admin on Sat Jun 26 08:26:22 UTC 2021
PRIMARY
RXCUI
1426899
Created by admin on Sat Jun 26 08:26:22 UTC 2021 , Edited by admin on Sat Jun 26 08:26:22 UTC 2021
PRIMARY RxNorm
CAS
750-90-3
Created by admin on Sat Jun 26 08:26:22 UTC 2021 , Edited by admin on Sat Jun 26 08:26:22 UTC 2021
PRIMARY
EVMPD
SUB15094MIG
Created by admin on Sat Jun 26 08:26:22 UTC 2021 , Edited by admin on Sat Jun 26 08:26:22 UTC 2021
PRIMARY
FDA UNII
6DY04L71DR
Created by admin on Sat Jun 26 08:26:22 UTC 2021 , Edited by admin on Sat Jun 26 08:26:22 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY
ACTIVE MOIETY